Bellerophon Therapeutics Inc
NASDAQ:BLPH
Bellerophon Therapeutics Inc
Cash from Financing Activities
Bellerophon Therapeutics Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Bellerophon Therapeutics Inc
NASDAQ:BLPH
|
Cash from Financing Activities
$5m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cash from Financing Activities
-$2.3B
|
CAGR 3-Years
-144%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-10%
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash from Financing Activities
$5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-73%
|
CAGR 10-Years
N/A
|
|
Stryker Corp
NYSE:SYK
|
Cash from Financing Activities
-$1.5B
|
CAGR 3-Years
-73%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-25%
|
|
Abbott Laboratories
NYSE:ABT
|
Cash from Financing Activities
-$7.1B
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-9%
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash from Financing Activities
$46.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
See Also
What is Bellerophon Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
5m
USD
Based on the financial report for Jun 30, 2023, Bellerophon Therapeutics Inc's Cash from Financing Activities amounts to 5m USD.
What is Bellerophon Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-28%
The average annual Cash from Financing Activities growth rates for Bellerophon Therapeutics Inc have been -56% over the past three years , -28% over the past five years .